» Articles » PMID: 31279828

Utilization of Herpesviridae As Recombinant Viral Vectors in Vaccine Development Against Animal Pathogens

Overview
Journal Virus Res
Specialty Microbiology
Date 2019 Jul 8
PMID 31279828
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Throughout the past few decades, numerous viral species have been generated as vaccine vectors. Every viral vector has its own distinct characteristics. For example, the family herpesviridae encompasses several viruses that have medical and veterinary importance. Attenuated herpesviruses are developed as vectors to convey heterologous immunogens targeting several serious and crucial pathogens. Some of these vectors have already been licensed for use in the veterinary field. One of their prominent features is their capability to accommodate large amount of foreign DNA, and to stimulate both cell-mediated and humoral immune responses. A better understanding of vector-host interaction builds up a robust foundation for the future development of herpesviruses-based vectors. At the time, many molecular tools are applied to enable the generation of herpesvirus-based recombinant vaccine vectors such as BAC technology, homologous and two-step en passant mutagenesis, codon optimization, and the CRISPR/Cas9 system. This review article highlights the most important techniques applied in constructing recombinant herpesviruses vectors, advantages and disadvantages of each recombinant herpesvirus vector, and the most recent research regarding their use to control major animal diseases.

Citing Articles

Recombinant Marek's disease virus expressing VP1 and VP2 proteins provides robust immune protection against chicken infectious anemia virus.

Ge C, Lu H, Han J, Sun G, Li S, Lan X Front Microbiol. 2025; 15():1515415.

PMID: 39834361 PMC: 11743625. DOI: 10.3389/fmicb.2024.1515415.


Development and immunogenicity evaluation of a quadruple-gene-deleted pseudorabies virus strain.

Li H, Zhang R, Qu J, Kang Y, Zhang J, Guo R Front Microbiol. 2024; 15:1479794.

PMID: 39372271 PMC: 11449858. DOI: 10.3389/fmicb.2024.1479794.


Immunological characteristics of a recombinant alphaherpesvirus with an envelope-embedded protein of circovirus.

Lu C, Li H, Chen W, Li H, Ma J, Peng P Front Immunol. 2024; 15:1438371.

PMID: 39081314 PMC: 11286414. DOI: 10.3389/fimmu.2024.1438371.


Simultaneous construction strategy using two types of fluorescent markers for HVT vector vaccine against infectious bursal disease and H9N2 avian influenza virus by NHEJ-CRISPR/Cas9.

Zhang J, Shang K, Kim S, Park J, Wei B, Jang H Front Vet Sci. 2024; 11:1385958.

PMID: 38812565 PMC: 11135205. DOI: 10.3389/fvets.2024.1385958.


Development of a Highly Efficient CRISPR/Cas9-Mediated Herpesvirus of Turkey-Based Vaccine against Novel Variant Infectious Bursal Disease Virus.

Zhang J, Park J, Kim S, Choi Y, Cha S, Jang H Vaccines (Basel). 2024; 12(3).

PMID: 38543860 PMC: 10974780. DOI: 10.3390/vaccines12030226.